DEXCOM INC — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-09-09

Reporting Person: Flynn Paul R (EVP, Global Revenue)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-09	Common Stock	S	743	$541.36	Disposed	11563	Direct
2021-09-09	Common Stock	S	9	$541.76	Disposed	11554	Direct
2021-09-10	Common Stock	S	626	$558.33	Disposed	10928	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: Included in this number are 10,928 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

F3: On December 11, 2020, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan.